Search

Your search keyword '"Szablewski, Vanessa"' showing total 191 results
Start Over Author "Szablewski, Vanessa"
191 results on '"Szablewski, Vanessa"'

3. Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations

Author

Nicolae, Alina, Bouilly, Justine, Lara, Diane, Fataccioli, Virginie, Lemonnier, François, Drieux, Fanny, Parrens, Marie, Robe, Cyrielle, Poullot, Elsa, Bisig, Bettina, Bossard, Céline, Letourneau, Audrey, Missiaglia, Edoardo, Bonnet, Christophe, Szablewski, Vanessa, Traverse-Glehen, Alexandra, Delfau-Larue, Marie-Hélène, de Leval, Laurence, and Gaulard, Philippe

Published
2022
Full Text
View/download PDF

4. Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey

Author

Syrykh, Charlotte, Chaouat, Charlotte, Poullot, Elsa, Amara, Nadia, Fataccioli, Virginie, Parrens, Marie, Traverse-Glehen, Alexandra, Molina, Thierry-Jo, Xerri, Luc, Martin, Laurent, Dubois, Romain, Lacheretz-Szablewski, Vanessa, Copin, Marie-Christine, Moreau, Anne, Chenard, Marie-Pierre, Cabarrou, Bastien, Lusque, Amélie, Gaulard, Philippe, Brousset, Pierre, and Laurent, Camille

Published
2022
Full Text
View/download PDF

7. Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma—Final Analysis.

Author

Maerevoet, Marie, Casasnovas, Olivier, Cartron, Guillaume, Morschhauser, Franck, Thieblemont, Catherine, Bouabdallah, Kamal, Feugier, Pierre, Szablewski, Vanessa, Becker, Stephanie, and Tilly, Herve

Subjects
THERAPEUTIC use of antineoplastic agents, PLATINUM compounds, CANCER relapse, RESEARCH funding, NON-Hodgkin's lymphoma, DISEASE duration, ANTINEOPLASTIC agents, CLINICAL trials, RITUXIMAB, ORAL drug administration, CANCER patients, DESCRIPTIVE statistics, CANCER chemotherapy, GEMCITABINE, DRUG efficacy, B cell lymphoma, DEXAMETHASONE
Abstract

Simple Summary: The chemotherapy combination rituximab, gemcitabine, and dexamethasone (R-GDP), followed by high-dose chemotherapy and autologous stem cell transplantation, is one of the standards of care for relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL). Complete metabolic response before transplantation is the most important prognosis factor for a long duration of remission. Selinexor is an oral, selective inhibitor of the nuclear export compound (XPO1). For heavily pretreated patients with DLBCL, the single drug selinexor has previously shown an overall response rate of 29%. In this study, we evaluated selinexor in combination with RGDP for patients with R/R B-cell lymphoma. The results from our phase I clinical study indicate that weekly selinexor plus RGDP has a generally tolerable safety profile and durable efficacy in R/R B-NHL. Purpose: Selinexor is an oral selective inhibitor of exportine-1 (XPO1) with efficacy as a single agent in heavily pretreated diffuse large B-cell lymphoma (DLBCL). We conducted a study investigating the combination of selinexor with rituximab and platinum-based chemotherapy in B-cell lymphoma. Patients and methods: We conducted a phase 1b, dose-escalation, and expansion trial, which enrolled patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Patients received oral selinexor according to a 3 + 3 design in combination with rituximab and dexamethasone, high-dose cytarabine, oxaliplatine (DHAOX) or gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy. Results: A total of 39 patients were enrolled, 27 during the escalation phase and 12 during the expansion phase. Most patients had diffuse large B-cell lymphoma (DLBCL; 77%). Group R-DHAOX was prematurely closed to inclusion due to a recommendation from the French drug agency, independent of this trial. A recommended phase 2 dose (RP2D) of selinexor in association with R-GPD was established at 40 mg on days 1, 8, and 15 of each 21-day cycle. In a population of 18 patients treated at this dose of selinexor, the most frequent grade 3–4 adverse events were hematological. With this regimen, seven obtained a complete metabolic response and five a partial response. The median PFS was 5.8 months. Conclusions: Among the patients with R/R B-cell lymphoma, selinexor at a weekly dose of 40 mg with R-GDP is feasible for outpatients, with a generally acceptable safety profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease

Author

Nann, Dominik, Ramis-Zaldivar, Joan Enric, Müller, Inga, Gonzalez-Farre, Blanca, Schmidt, Janine, Egan, Caoimhe, Salmeron-Villalobos, Julia, Clot, Guillem, Mattern, Sven, Otto, Franziska, Mankel, Barbara, Colomer, Dolors, Balagué, Olga, Szablewski, Vanessa, Lome-Maldonado, Carmen, Leoncini, Lorenzo, Dojcinov, Stefan, Chott, Andreas, Copie-Bergman, Christiane, Bonzheim, Irina, Fend, Falko, Jaffe, Elaine S., Campo, Elias, Salaverria, Itziar, and Quintanilla-Martinez, Leticia

Published
2020
Full Text
View/download PDF

10. Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation

Author

Trecourt, Alexis, Mauduit, Claire, Szablewski, Vanessa, Fontaine, Juliette, Balme, Brigitte, Donzel, Marie, Laurent, Camille, Sesques, Pierre, Ghesquières, Hervé, Bachy, Emmanuel, Salles, Gilles, Emile, Jean-François, Chassagne-Clément, Catherine, Genestier, Laurent, Copie-Bergman, Christiane, and Traverse-Glehen, Alexandra

Published
2022
Full Text
View/download PDF

11. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma

Author

Lamy, Thierry, Damaj, Gandhi, Soubeyran, Pierre, Gyan, Emmanuel, Cartron, Guillaume, Bouabdallah, Krimo, Gressin, Rémy, Cornillon, Jérôme, Banos, Anne, Le Du, Katell, Benchalal, Mohamed, Moles, Marie-Pierre, Le Gouill, Steven, Fleury, Joel, Godmer, Pascal, Maisonneuve, Hervé, Deconinck, Eric, Houot, Roch, Laribi, Kamel, Marolleau, Jean Pierre, Tournilhac, Olivier, Branger, Bernard, Devillers, Anne, Vuillez, Jean Philippe, Fest, Thierry, Colombat, Philippe, Costes, Valérie, Szablewski, Vanessa, Béné, Marie C., Delwail, Vincent, and on behalf of the LYSA Group

Published
2018
Full Text
View/download PDF

17. Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study

Author

Maerevoet, Marie, primary, Casasnovas, Olivier, additional, Cartron, Guillaume, additional, Morschhauser, Franck, additional, Thieblemont, Catherine, additional, Bouabdallah, Kamal, additional, Feugier, Pierre, additional, Szablewski, Vanessa, additional, Becker, Stéphanie, additional, and Tilly, Hervé, additional

Published
2022
Full Text
View/download PDF

18. Clinical Features, Histological Characteristics, and Disease Outcomes of Mycosis Fungoides in Children and Adolescents: A Nationwide Multicentre Cohort of 46 Patients

Author

Welfringer-Morin, Anne, primary, Barroil, Marion, additional, Fraitag, Sylvie, additional, Szablewski, Vanessa, additional, Boccara, Olivia, additional, Lacour, Jean-Philippe, additional, Chiaverini, Christine, additional, Bagot, Martine, additional, Ram-Wolff, Caroline, additional, Vignon-Pennamen, Marie-Dominique, additional, Dalle, Stéphane, additional, D’incan, Michel, additional, Amatore, Florent, additional, Beylot-Barry, Marie, additional, Vergier, Béatrice, additional, Mazereeuw-Hautier, Juliette, additional, Tedbirt, Billal, additional, Quereux, Gaelle, additional, Carpentier, Olivier, additional, Skowron, Francois, additional, Bertrand, Yves, additional, Van Eeckhout, Pascal, additional, Dekeuleneer, Valérie, additional, Nardin, Charlee, additional, Adamski, Henri, additional, Ingen-Housz-Oro, Saskia, additional, Dereure, Olivier, additional, and Bodemer, Christine, additional

Published
2022
Full Text
View/download PDF

19. Cutaneous vasculitis associated with mycosis fungoides

Author

Nardin, Charlée, primary, Lesage, Candice, additional, Goubeau, Eléonore, additional, Aubriot‐Lorton, Marie‐Helene, additional, Lacheretz‐Szablewski, Vanessa, additional, Ortonne, Nicolas, additional, Saizonou, Ines, additional, Aubin, François, additional, Dereure, Olivier, additional, and Dalac‐Rat, Sophie, additional

Published
2022
Full Text
View/download PDF

23. Clinical presentation, outcome, and prognostic markers in patients with intravascular large B‐cell lymphoma, a lymphoma study association (LYSA) retrospective study

Author

Bonnet, Antoine, primary, Bossard, Céline, additional, Gabellier, Ludovic, additional, Rohmer, Julien, additional, Laghmari, Othman, additional, Parrens, Marie, additional, Sarkozy, Clémentine, additional, Dulery, Rémy, additional, Roland, Virginie, additional, Llamas‐Gutierrez, Francisco, additional, Oberic, Lucie, additional, Fornecker, Luc‐Matthieu, additional, Bounaix, Laura, additional, Villemagne, Bruno, additional, Szablewski, Vanessa, additional, Choquet, Sylvain, additional, Bouabdallah, Krimo, additional, Traverse‐Glehen, Alexandra, additional, Mohty, Mohamad, additional, Sanhes, Laurence, additional, Houot, Roch, additional, Gastinne, Thomas, additional, Leux, Christophe, additional, and Le Gouill, Steven, additional

Published
2022
Full Text
View/download PDF

26. Clinical Features, Histological Characteristics, and Disease Outcomes of Mycosis Fungoides in Children and Adolescents: A Nationwide Multicentre Cohort of 46 Patients.

Author

Welfringer-Morin, Anne, Barroil, Marion, Fraitag, Sylvie, Szablewski, Vanessa, Boccara, Olivia, Lacour, Jean-Philippe, Chiaverini, Christine, Bagot, Martine, Ram-Wolff, Caroline, Vignon-Pennamen, Marie-Dominique, Dalle, Stéphane, D'incan, Michel, Amatore, Florent, Beylot-Barry, Marie, Vergier, Béatrice, Mazereeuw-Hautier, Juliette, Tedbirt, Billal, Quereux, Gaelle, Carpentier, Olivier, and Skowron, Francois

Subjects
MYCOSIS fungoides, TEENAGERS, JUVENILE diseases, SEX ratio, CD8 antigen, PATIENT surveys
Abstract

Background: Our objective was to describe the clinical, histological characteristics, and disease outcome of a cohort of mycosis fungoides (MF) diagnosed during childhood including disease status at adulthood. Methods: This is a retrospective multicentre survey of patients aged under 18 years at diagnosis with histologically confirmed MF. Patients' clinical and histological characteristics, treatments, and disease outcome (for patients followed for more than 12 months) were analysed. Results: Forty-six patients were included (median age at diagnosis: 11 years; M:F sex ratio: 3:1) with 39 (85%) followed for at least 12 months. Thirty-nine patients (85%) had stage I MF. Hypopigmented patches were observed in 48% and folliculotropism in 43% patients. Immunophenotype of the skin infiltrate was predominantly CD8+ in 17% of patients. Initial management included a wait-and-see strategy in 6/39 (15%), skin-directed treatment in 27 (69%), and systemic treatment in 6 (15%) patients, respectively, with partial or complete clinical response (PR or CR) observed in 28 patients (72%). 14/39 patients (36%) relapsed after initial response. After a median follow-up period of 54 months, disease status at last news was PR or CR in 31/39 (79%), stable disease in 6 (15%), and progression in 2 (5%) patients. Histological transformation was observed in 3/39 (8%). Of the 15 patients followed until adulthood, 13 (87%) had persistent MF. Discussion: This survey confirms the high frequency of hypopigmented and folliculotropic lesions and of CD8+ immunophenotype compared to adult MF patients. The long-term course is usually indolent but transformation may occur sometimes long after disease onset and the disease may persist during adulthood. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas

Author

Julia, Edith, primary, Mareschal, Sylvain, additional, Chebel, Amel, additional, Golfier, Camille, additional, Müller, Tony Andreas, additional, Lours, Camille, additional, Hadj-Hamou, Sofiane, additional, Bissay, Nathalie, additional, Tschanz, Manon, additional, Ceribelli, Michele, additional, Chartoire, Dimitri, additional, Vernay, Aurélie, additional, Carras, Sylvain, additional, Sibon, David, additional, Marçais, Ambroise, additional, Laurent, Camille, additional, Martin, Laurent, additional, Asnafi, Vahid, additional, Payen, Lea, additional, Sanlaville, Damien, additional, Bardel-Danjean, Claire, additional, Roussel, Mikael, additional, Szablewski, Vanessa, additional, Drieux, Fanny, additional, Ruminy, Philippe, additional, Herling, Marco, additional, Chassagne-Clément, Catherine, additional, Salles, Gilles, additional, Sujobert, Pierre, additional, Traverse-Glehen, Alexandra, additional, Baseggio, Lucile, additional, De Leval, Laurence, additional, Staudt, Louis M., additional, Gaulard, Philippe, additional, Genestier, Laurent, additional, and Bachy, Emmanuel, additional

Published
2021
Full Text
View/download PDF

28. Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Results of the Selinda Phase Ib Lysa Study

Author

Maerevoet, Marie, primary, Casasnovas, Olivier, additional, Cartron, Guillaume, additional, Morschhauser, Franck, additional, Thieblemont, Catherine, additional, Bouabdallah, Kamal, additional, Feugier, Pierre, additional, Szablewski, Vanessa, additional, Becker, Stephanie, additional, and Tilly, Hervé, additional

Published
2021
Full Text
View/download PDF

29. Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas

Author

Trecourt, Alexis, primary, Mauduit, Claire, additional, Szablewski, Vanessa, additional, Fontaine, Juliette, additional, Balme, Brigitte, additional, Donzel, Marie, additional, Laurent, Camille, additional, Sesques, Pierre, additional, Ghesquières, Hervé, additional, Bachy, Emmanuel, additional, Salles, Gilles, additional, Emile, Jean-François, additional, Chassagne-Clément, Catherine, additional, Genestier, Laurent, additional, Copie-Bergman, Christiane, additional, and Traverse-Glehen, Alexandra, additional

Published
2021
Full Text
View/download PDF

31. [Impact of algorithms proposed by the Cutaneous Lymphoma French Study Group for diagnosis of cutaneous lymphoproliferations]

Author

Menguy, Sarah, Mansour, Yara, Jullié, Marie-Laure, Augereau, Olivier, Ortonne, Nicolas, Balme, Brigitte, Battistella, Maxime, Lamant, Laurence, Beltzung, Fanny, Szablewski, Vanessa, Gaulard, Philippe, Bagot, Martine, Beylot-Barry, Marie, Vergier, Béatrice, Université de Bordeaux (UB), CHU Bordeaux [Bordeaux], Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], CHU Clermont-Ferrand, Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and Hôpital Henri Mondor

Subjects
MESH: Humans, Skin Neoplasms, MESH: Skin Neoplasms, MESH: Algorithms, MESH: Retrospective Studies, MESH: Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Cutaneous, Cutaneous lymphoma, Diagnostic algorithms, Lymphomes cutanés, MESH: Sezary Syndrome, Algorithme diagnostique, Humans, Sezary Syndrome, French Study Group of Cutaneous Lymphomas, Groupe français d’étude des lymphomes cutanés, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Algorithms, Retrospective Studies
Abstract

International audience; After a first diagnosis proposition, management of cutaneous lymphomas requires a systematic review by an expert pathologist and each case is presented to a multidisciplinary meeting in the setting of the French Study Group of Cutaneous Lymphomas to propose an adequate treatment. A retrospective study of the 2760 cutaneous lymphoproliferations retrieved between 2010 and 2011 were analyzed and demonstrated the interest of diagnostic algorithms we built with the group. The objective of our study was to compare two cohorts from 2010-2011 and 2015-2017 regarding the proportion of cases sent for validation or expertise, the concordance and mismatch rates and potential diagnostic issues using our diagnostic algorithms. Between 2015-2017, 5640 skin lymphoproliferation cases were examined. It appeared that Pathologists were more confident and effective in finding the right diagnosis. Indeed, the rate of concordant diagnosis increased from 57% to 67%. Moreover, in comparison with the 2010-2011 concordant cases sent for expertise, 73.5% of concordant cases were sent for validation in 2015-2017. 14% of cases remained discordant, mainly sent for expertise. Furthermore, half of questionable cases (26.3%) were resolved after expertise, and 12.1% cases remained unsolved. These priority cases are important to be presented at multidisciplinary meeting. The analysis of discordant and doubtful cases unveiled recurrent diagnostic problems for which we proposed appropriate diagnostic algorithms including large B cell lymphomas, CD4+ T cell lymphoproliferations, epidermotropic CD8+ T-cell lymphoproliferations and the differential diagnosis of mycosis fongoïdes/Sezary syndrome versus inflammatory dermatitis.

Published
2020

32. HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma

Author

Sonigo, Gabrielle, Battistella, Maxime, Beylot-Barry, Marie, Ingen-Housz-Oro, Saskia, Franck, Nathalie, Barète, Stéphane, Boulinguez, Serge, Dereure, Olivier, Bonnet, Nathalie, Brice, Pauline, Boccara, Olivia, Bodemer, Christine, Adamski, Henri, D'Incan, Michel, Ortonne, Nicolas, Fraitag, Sylvie, Brunet-Possenti, Florence, Dalle, Stéphane, Suarez, Felipe, Skowron, François, Haidar, Dima, Maubec, Eve, Bohelay, Gerome, Laroche, Liliane, Mahé, Antoine, Birckel, Elodie, Bouaziz, Jean-David, Brocheriou, Isabelle, Dubois, Romain, Faiz, Sarah, Fadlallah, Jehane, Ram-Wolff, Caroline, Carlotti, Agnès, Bens, Guido, Balme, Brigitte, Vergier, Béatrice, Laurent-Roussel, Sara, Deschamps, Lydia, Carpentier, Olivier, Moguelet, Philippe, Herve, Genevieve, Comoz, Francois, Le Gall, François, Leverger, Guy, Finon, Antoine, Augereau, Olivier, Blechet, Claire, Kerdraon, Rémy, Lamant, Laurence, Tournier, Emilie, Franck, Frédéric, Costes-Martineau, Valérie, Szablewski, Vanessa, Taix, Sebastien, Beschet, Isabelle, Guérin, Frédéric, Sepulveda Garrido, Fernando, Bagot, Martine, De Saint Basile, Geneviève, Michonneau, David, de Masson, Adèle, Socié, Gérard, Bodemer, Shristine ChB, Marçais, Ambroise, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Bordeaux [Bordeaux], CHU Henri Mondor, Service de Dermatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Toulouse [Toulouse], Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), Hôpital Nord [CHU - APHM], Service d'Hémato-oncologie [CHU Saint-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Necker - Enfants Malades [AP-HP], Service de dermatologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], CHU Pontchaillou [Rennes], CHU Clermont-Ferrand, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service d'immuno-hématologie pédiatrique [CHU Necker], Centre Hospitalier de Valence (CH DE VALENCE), Centre hospitalier de Valence, Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Avicenne [AP-HP], Hôpital pasteur [Colmar], Service de Dermatologie [AP-HP Hôpital Saint-Louis], Service d'Anatomie et cytologie pathologiques [CHU Pitié-Salpêtrière] (ACP), Mouvement, Équilibre, Performance, Santé (MEPS), Université de Pau et des Pays de l'Adour (UPPA), Service de Dermatologie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Service de dermatologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiopathologie du cancer du foie, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2, Service de pathologie [CHU Bichat], Service d’Anatomie et cytologie pathologiques [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Pathologies Respiratoires : Protéolyse et Aérosolthérapie, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional d'Orléans (CHRO), Service d'anatomie et cytologie pathologiques [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Institut Cochin (IC UM3 (UMR 8104 / U1016)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Laboratoire d'aérologie (LAERO), Centre National de la Recherche Scientifique (CNRS)-Observatoire Midi-Pyrénées (OMP), Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Unité d'hématologie et de transplantation, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Service d’anatomie et cytologie pathologiques [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'anatomie et cytologie pathologiques [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Centre Hospitalier Régional d'Orléans (CHR), Laboratoire d'aérologie (LA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS), Immunologie humaine, physiopathologie & immunithérapie (HIPI (UMR_S_976 / U976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'Anatomie et cytologie pathologiques = Service de Pathologie [CHU Pitié-Salpêtrière] (ACP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d'Anatomie et cytologie pathologiques [CHU Tenon], CHU Tenon [AP-HP], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Anatomie et cytologie pathologiques [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), COLO, Mouniati, Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Henri Mondor [Créteil], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse], Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Pathology, medicine.medical_specialty, Panniculitis, [SDV]Life Sciences [q-bio], Immunology, 2 supplemental tables, [SDV.CAN]Life Sciences [q-bio]/Cancer, Lymphoma, T-Cell, HAVCR2, Biochemistry, Lymphohistiocytosis, Hemophagocytic, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Subcutaneous Panniculitis-Like T-Cell Lymphoma, 9 references Article type: Letter Scientific category: Lymphoma, Humans, Medicine, Genetic Predisposition to Disease, Hepatitis A Virus Cellular Receptor 2, Genetic Association Studies, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, 0303 health sciences, Hemophagocytic lymphohistiocytosis, business.industry, Cell Biology, Hematology, medicine.disease, 3. Good health, Lymphoma, [SDV] Life Sciences [q-bio], 1 supplemental figure, 030220 oncology & carcinogenesis, Mutation, Mutation (genetic algorithm), 2 tables, Female, business, Biomarkers
Abstract

International audience

Published
2020

34. Outcome and clinicophenotypical features of acute lymphoblastic leukemia/lymphoblastic lymphoma with cutaneous involvement: A multicenter case series

Author

Bontoux, Christophe, primary, De Masson, Adèle, additional, Boccara, Olivia, additional, Bodemer, Christine, additional, Fraitag, Sylvie, additional, Balme, Brigitte, additional, Franck, Nathalie, additional, Carlotti, Agnès, additional, Comoz, François, additional, Verneuil, Laurence, additional, Brasme, Jean-François, additional, Duplan, Mylène, additional, Croué, Anne, additional, Templier, Isabelle, additional, Beltraminelli, Helmut, additional, Dereure, Olivier, additional, Szablewski, Vanessa, additional, Thevenin, Céline, additional, Boulinguez, Serge, additional, Viraben, Roland, additional, Tournier, Emilie, additional, Lamant, Laurence, additional, Ortonne, Nicolas, additional, Ingen-Housz-Oro, Saskia, additional, Beckerich, Florence, additional, Grange, Florent, additional, Durlach, Anne, additional, Amatore, Florent, additional, Frouin, Eric, additional, McIntyre, Elizabeth, additional, Asnafi, Vahid, additional, Kim, Rathana, additional, Clappier, Emmanuelle, additional, Soulier, Jean, additional, Boissel, Nicolas, additional, Dombret, Hervé, additional, Bagot, Martine, additional, and Battistella, Maxime, additional

Published
2020
Full Text
View/download PDF

37. Cutaneous vasculitis associated with mycosis fungoides.

Author

Nardin, Charlée, Lesage, Candice, Goubeau, Eléonore, Aubriot‐Lorton, Marie‐Helene, Lacheretz‐Szablewski, Vanessa, Ortonne, Nicolas, Saizonou, Ines, Aubin, François, Dereure, Olivier, and Dalac‐Rat, Sophie

Subjects
MYCOSIS fungoides, SEZARY syndrome, VASCULITIS, CUTANEOUS T-cell lymphoma
Abstract

Biopsies of these lesions revealed a dermal infiltration of CD3+ CD4+ CD8- CD30- atypical lymphocytes with both pilotropism and epidermotropism without transformation adjacent to vasculitis and lymphohistiocytic infiltrate. In a case series of 19 SMF patients, Masson et al[2] reported five patients (26%) with cutaneous lesions (ulcers and livedoid lesions) consistent with CV but not histologically confirmed. [Extracted from the article]

Published
2023
Full Text
View/download PDF

38. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas

Author

Alame, Melissa, primary, Pirel, Marion, additional, Costes-Martineau, Valérie, additional, Bauchet, Luc, additional, Fabbro, Michel, additional, Tourneret, Alicia, additional, De Oliveira, Laura, additional, Durand, Luc, additional, Roger, Pascal, additional, Gonzalez, Samia, additional, Cacheux, Valère, additional, Rigau, Valérie, additional, and Szablewski, Vanessa, additional

Published
2019
Full Text
View/download PDF

39. Role of epigenetic modifiers in diffuse large B cell lymphoma pathophysiology

Author

Szablewski, Vanessa, Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Université Montpellier, and Valérie Martineau-Costes

Subjects
hemic and lymphatic diseases, Épigénétique, Pronostic, Lymphome B, Epigenetics, Prognosis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, B cell lymphoma
Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma type. DLBCL shows considerable clinical and biological heterogeneity. The international prognostic index (IPI) remains the most used tool to stratify patients in different risk groups but does not reflect DLBCL biological heterogeneity. Therefore, much research is currently focused on the identification of new prognostic markers for more specific patients’ risk stratification and on the development of therapeutic approaches to improve outcome. Epigenetic alterations are involved in lymphoma. Interestingly, epigenetic alterations are reversible and drugs to target some of them have been developed. With the aim to identify new and relevant prognostic factors that allow the stratification of patients with DLBCL we investigated the gene expression profile of 130 epigenetics regulators in two independent cohorts of patients with newly-diagnosed DLBCL homogeneously treated (respectively 233 and 181 cases). Using the Maxstat R function and Benjami-Hochberg multiple testing correction we found that 10 probe sets had a prognostic value for overall survival (OS) including: BRD1, CARM1, BRPF3, CDYL, DNMT3A, DOT1L, HDAC2, PRMT5, SETD8 and SP140. Using multivariate Cox analysis we found that 3 of these genes remained independent prognostic factors: DNMT3A, DOT1L and SETD8. We used these 3 genes to develop a risk score (EpiScore) based on their expression level in the cohort of 233 DLBCL. EpiScore allowed splitting the patients in 3 groups with significant different OS values: group 1 (low risk, low DNMT3A, DOT1L and SETD8 expression), group 2 (intermediate risk, high expression of one of the three genes) and group 3 (high risk, high expression of two or all three genes). EpiScore prognostic value was validated in two other independent cohorts of patients with DLBCL (181 and 69 patients respectively) We then showed that EpiScore was an independent predictor of survival when compared with previously described prognostic factors, such as the IPI, germinal center B cell and activated B cell molecular subgroups, gene expression-based risk score (GERS) and DNA repair score. As gene expression profiling (GEP) is not a technical approach widely performed in routine practise for all DLBCL newly diagnosed we analysed the pattern of expression of the ten epigenetic genes by immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) tissue sections in a cohort of 65 patients with de novo previously untreated DLBCL. Our results indicate that these epigenetic related proteins are commonly overexpressed in DLBCL compared to reactive lymphoid tissues and may be important for DLBCL pathogenesis. We showed that overexpression of CARM1 and DNMT3A was significantly associated with reduced event free survival. We then designed a new risk score Epi-ImmunoScore (Epi-IS) based on the expression level of CARM1 and DNMT3A by immunohistochemistry. Epi-IS was predictive of OS in DLBCL and allowed splitting patients in two groups (high and low risk). Finally, using gene set enrichment analysis (GSEA) an HDAC gene signature was significantly enriched in the DLBCL samples included in the EpiScore high-risk group and that a significant enrichment of genes encoding for HDAC class II, multiple drug resistance and NOTCH pathways in DLBCL samples with DNMT3A overexpression. According to these data, we compared the response to HDAC inhibitor (SAHA) in DLBCL cell lines with high EpiScore versus low EpiScore and showed that DLBCL cell lines with high EpiScore were significantly more sensitive to SAHA than those low EpiScore. We concluded that EpiScore and Epi-IS, easily evaluated in the routine practice on FFPE tissue sections identified high-risk patients with DLBC. We have also recognized relevant therapeutic targets and identified a number of candidate drugs with potential therapeutic efficiency in DLBCL patients. All these findings may orient future preclinical intervention strategies in DLBCL.; Les lymphomes B diffus à grandes cellules (DLBCL) sont le type le plus fréquent de lymphome et montrent une hétérogénéité clinique et biologique. L’index pronostique international (IPI) reste le meilleur outil permettant de stratifier les patients en groupes pronostiques mais n’est pas le reflet de leur hétérogénéité biologique. Les travaux de recherches se sont concentrés sur l’identification de nouveaux marqueurs pronostiques afin de stratifier les patients de manière optimale et de développer de nouvelles thérapeutiques améliorant la survie. Les altérations épigénétiques sont impliquées dans les lymphomes. Ces altérations sont réversibles et des drogues les ciblant existent. Dans le but d’identifier de nouveaux marqueurs pronostiques pertinents permettant de stratifier les patients avec un DLBCL nous avons étudié les données d’expression génique de 130 régulateurs épigénétiques dans 2 cohortes de patients avec un DLBCL au diagnostic (respectivement 233 et 181 cas). La fonction Maxstat R et la procédure de correction statistique Benjami-Hochberg nous ont permis de sélectionner 10 gènes avec un impact pronostique significatif sur la survie globale (OS) : BRD1, CARM1, BRPF3, CDYL, DNMT3A, DOT1L, HDAC2, PRMT5, SETD8 and SP140. Trois gènes conservaient une valeur pronostique indépendante en analyses multivariées : DNMT3A, DOT1L, SETD8. Ces 3 gènes nous ont permis de construire un score pronostique EpiScore basé sur leur niveau d’expression dans la cohorte principale de 233 DLBCL. L’EpiScore permettait de stratifier les patients en 3 groupes d’OS significativement différente : groupe 1 (faible risque, faible expression des 3 gènes), groupe 2 (risque intermédiaire, forte expression d’1 des 3 gènes), groupe 3 (haut risque, forte expression d’au moins 2 des 3 gènes). La valeur pronostique de l’EpiScore a ensuite été validée dans 2 autres cohortes de DLBCL (181 et 69 patients). L’EpiScore conservait sa valeur pronostique indépendante en terme d’OS comparativement aux autres facteurs pronostiques : IPI, sous groupe moléculaire GC versus ABC, gene expression-based risk score (GERS) et le DNA repair score. L’étude des profils d’expression génique a partir d’’ARN n’est pas une technique facilement applicable en routine diagnostique. Nous avons donc évalué les patterns d’expression protéique des 10 gènes initiaux par immunohistochimie sur coupes de paraffine de tumeur de 65 patients avec un DLBCL au diagnostic. Nos résultats montraient que ces modulateurs épigénétiques étaient surexprimés dans les DLBCL comparativement au tissu lymphoïde normal. La surexpression protéique de CARM1 et de DNMT3A était en outre associée une survie sans événement significativement réduite. Nous avons donc établi un nouveau score l’Epi-Immunoscore (Epi-IS) basé sur le niveau d’expression de ces 2 protéines en immunohistochimie. Nous avons montré la valeur prédictive sur l’OS de l’Epi-IS qui permettait de diviser les patients en 2 groupes (faible et haut risque). Finalement en appliquant des analyses en GSEA (gene set enrichment analysis) nous avons observé que les patients EpiScore haut risque avait une signature enrichie en gènes de la voie HDAC et que les échantillons de DLBCL montrant une surexpression de DNMT3A avait des signatures enrichis en gènes des voies HDAC class II, NOTCH et multiple drug resistance. Nous avons donc comparé la réponse aux inhibiteurs des HDAC (HDACi) des lignées cellulaires de DLBCL EpiScore fort versus faible. Les lignées de DLBCL EpiScore fort étaient significativement plus sensibles aux HDCAi que celles EpiScore faible. Nous avons conclu que l’EpiScore et l’Epi-IS, facilement applicable en routine diagnostique sur coupes de paraffine, permettaient d’identifier les patients avec un DLBCL à haut risque. Nous avons également identifié des cibles thérapeutiques pertinentes et un certains de nombres de drogues potentiellement efficaces. Toutes ces données pourraient orienter de futurs essais pré-cliniques dans les DLBCL.

Published
2019

42. Primary cutaneous large B‐cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases

Author

Menguy, Sarah, primary, Beylot‐Barry, Marie, additional, Parrens, Marie, additional, Ledard, Anne‐Pham, additional, Frison, Eric, additional, Comoz, François, additional, Battistella, Maxime, additional, Szablewski, Vanessa, additional, Balme, Brigitte, additional, Croue, Anne, additional, Franck, Frédéric, additional, Ortonne, Nicolas, additional, Tournier, Emilie, additional, Lamant, Laurence, additional, Carlotti, Agnès, additional, De Muret, Anne, additional, Le Gall, François, additional, Lorton, Marie‐Hélène, additional, Merlio, Jean‐Philippe, additional, and Vergier, Béatrice, additional

Published
2019
Full Text
View/download PDF

43. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival

Author

Four, Marion, Cacheux, Valère, Tempier, Ariane, Platero, Dolorès, Fabbro, Michel, Marin, Grégory, Leventoux, Nicolas, Rigau, Valérie, Costes-Martineau, Valérie, Szablewski, Vanessa, Service de Biopathologie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle (ICM), CRLCC Val d'Aurelle - Paul Lamarque, Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )

Subjects
Adult, Aged, 80 and over, Male, Programmed Cell Death 1 Receptor, lymphoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, central nervous system, B7-H1 Antigen, Central Nervous System Neoplasms, PD1, immune system diseases, hemic and lymphatic diseases, PDL1, Biomarkers, Tumor, Humans, Female, Lymphoma, Large B-Cell, Diffuse, neoplasms, Aged, Retrospective Studies
Abstract

International audience; Primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) is a rare and aggressive type of diffuse large B-cell lymphoma (DLBCL) whit poorly understood pathogenesis. Finding biomarkers associated with patient survival may be important for understanding its physiopathology and to develop new therapeutic approaches. We investigated 32 PCNS-DLBCL from immunocompetent patients for BCL2, CMYC, LMO2, and P53 expression and for cytogenetic aberrations of BCL2, BCL6, and MYC genes, all known for their prognostic value in systemic DLBCL (s-DLBCL). We analyzed PD1 and PDL1 protein expression in both tumor infiltrating lymphocytes (TILs) and tumor cells. Finally, we searched for correlation between biological data and clinical course. The PCNS-DLBCL expressed BCL2, CMYC, LMO2, and P53 at similar frequency than s-DLBCL but without significant prognostic on survival. None cases harbored aberrations involving BCL2 and MYC gene whereas BCL6 abnormalities were present in 20.7% of cases but without value on survival. Expression of PD1 in TILs and PDL1 in tumor cells was observed at higher rates than in s-DLBCL (58% and 37%, respectively). The PD1 expression in TILs correlated with PDL1 expression in tumor cells (P = .001). Presence of PD1 positive TILs was associated with poorer overall survival (P = .011). Patients with PDL1 overexpression tended to better response to chemotherapy (P = .23). In conclusion PCNS-DLBCL pathogenesis differs from s-DLBCL without prognostic value of the phenotypic and cytogenetic parameters known for their pejorative impact in the latter. The PD1/PDL1 pathway plays a strong role in PCNS-DLBCL and represents an attractive target for this aggressive lymphoma.

Published
2017

48. Primary Cutaneous Follicle Center Lymphomas Expressing BCL2 Protein Frequently Harbor BCL2 Gene Break and May Present 1p36 Deletion

Author

Szablewski, Vanessa, Ingen-Housz-Oro, Saskia, Baia, Maryse, Delfau-Larue, Marie-Hélène, Copie-Bergman, Christiane, Ortonne, Nicolas, Service de Biopathologie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Service de dermatologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Henri Mondor, Département de pathologie [Mondor], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10

Subjects
immune system diseases, hemic and lymphatic diseases, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, biological phenomena, cell phenomena, and immunity, neoplasms
Abstract

International audience; The classification of cutaneous follicular lymphoma (CFL) into primary cutaneous follicle center lymphoma (PCFCL) or secondary cutaneous follicular lymphoma (SCFL) is challenging. SCFL is suspected when tumor cells express BCL2 protein, reflecting a BCL2 translocation. However, BCL2 expression is difficult to assess in CFLs because of numerous BCL2+ reactive T cells. To investigate these issues and to further characterize PCFCL, we studied a series of 25 CFLs without any extracutaneous disease at diagnosis, selected on the basis of BCL2 protein expression using 2 BCL2 antibodies (clones 124 and E17) and BOB1/BCL2 double immunostaining. All cases were studied using interphase fluorescence in situ hybridization with BCL2, BCL6, IGH, IGK, IGL breakapart, IGH-BCL2 fusion, and 1p36/1q25 dual-color probes. Nineteen CFLs were BCL2 positive, and 6 were negative. After a medium follow-up of 24 (6 to 96) months, 5 cases were reclassified as SCFL and were excluded from a part of our analyses. Among BCL2+ PCFCLs, 60% (9/15) demonstrated a BCL2 break. BCL2-break-positive cases had a tendency to occur in the head and neck and showed the classical phenotype of nodal follicular lymphoma (CD10+, BCL6+, BCL2+, STMN+) compared with BCL2-break-negative PCFCLs. Del 1p36 was observed in 1 PCFCL. No significant clinical differences were observed between BCL2+ or BCL2- PCFCL. In conclusion, we show that a subset of PCFCLs harbor similar genetic alterations, as observed in nodal follicular lymphomas, including BCL2 breaks and 1p36 deletion. As BCL2 protein expression is usually associated with the presence of a BCL2 translocation, fluorescence in situ hybridization should be performed to confirm this hypothesis.

Published
2016

49. BCL2and BCL6atypical/unbalanced gene rearrangements in diffuse large B-cell lymphoma are indicators of an aggressive clinical course

Author

Tourneret, Alicia, Alame, Melissa, Rigau, Valerie, Bauchet, Luc, Fabbro, Michel, De Oliveira, Laura, Cacheux, Valere, Costes, Valerie, and Lacheretz-Szablewski, Vanessa

Abstract

AimsDiffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin's lymphoma that represents a heterogeneous group of disease that is differentially characterised by clinical, molecular and cytogenetic features. MYC, BCL2and BCL6gene rearrangements have been identified as prognostic factors in DLBCL, especially for MYC. Nevertheless the frequency and effect of atypical/unbalanced BCL6, BCL2and MYCtranslocations in DLBCL is not fully documented. Here, we aimed to analyse those atypical/unbalanced rearrangements in DLBCL and to assess their prognostic impact.MethodsWe collected tumour tissue and clinical data from 97 DLBCL and used interphase fluorescence in situ hybridisation (FISH) with break-apart probe to characterise BCL6, BCL2and MYCgene pattern.Results19 of 97 (19,6%) cases of DLBCL had atypical/ unbalanced gene rearrangements (14 involving BCL6gene, 5 involving BCL2gene and none involving MYCgene). Compared with patients with simple gene rearrangement and patients without cytogenetic abnormality, patients with atypical/unbalanced gene rearrangement were in an unfavourable risk group by the International Prognostic Index (p=0039), died of disease (p=0012), harboured relapse or progression (p=0011) and had shorter overall (p=0,04), relapse free (p=0029) and event free (p=0026) survival.ConclusionsWe showed that patients with DLBCL with BCL2or BCL6atypical/unbalanced rearrangements constituted a group of patients with poor outcome. We also underlined the importance of FISH analyses, easily feasible in routine practise, at diagnosis of DLBCL to detect the rather frequent and clinically significant atypical/unbalanced aberrations of these genes.

Published
2021
Full Text
View/download PDF

50. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches

Author

Vendrell, Julie A., primary, Taviaux, Sylvie, additional, Béganton, Benoît, additional, Godreuil, Sylvain, additional, Audran, Patricia, additional, Grand, David, additional, Clermont, Estelle, additional, Serre, Isabelle, additional, Szablewski, Vanessa, additional, Coopman, Peter, additional, Mazières, Julien, additional, Costes, Valérie, additional, Pujol, Jean-Louis, additional, Brousset, Pierre, additional, Rouquette, Isabelle, additional, and Solassol, Jérôme, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results